Mirvetuximab Soravtansine in Ovarian Cancer: Clinical Perspectives and Key Insights from MIRASOL
Panelists discuss how the Mirasol trial's demonstration of superior response rates (42% vs 15.9%) and overall survival (16.5 months) for the FDA-approved folate receptor alpha-positive ADC represents a revolutionary advancement in platinum-resistant ovarian cancer treatment, offering patients prolonged responses with better tolerability and quality of life compared to standard chemotherapies.
Impact of the Mirasol Trial on ADCs in Ovarian Cancer
ADCs are revolutionizing ovarian cancer treatment, particularly for platinum-resistant disease. The FDA-approved ADC for folate receptor alpha-positive patients demonstrated superior response rates and overall survival in the Mirasol trial compared to standard chemotherapies. The trial showed an objective response rate of 42% versus 15.9%, and overall survival extended to 16.5 months.
These findings mark one of the few significant overall survival improvements in this setting since bevacizumab doublets. Real-world use of the ADC has yielded prolonged responses and better tolerability, offering hope for long-term disease control with manageable side effects when closely monitored.
Clinicians report patients tolerate the ADC well, with many staying on therapy longer than traditional options. Side effects differ from standard chemo, often allowing patients to maintain a higher quality of life. Ocular toxicity is the most notable concern but is manageable with proactive care and early intervention.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
